A step towards removing plasma volume variance from the Athlete's Biological Passport: The use of biomarkers to describe vascular volumes from a simple blood test.

Autor: Lobigs LM; Department of Sport Science, Exercise and Health, School of Human Sciences, University of Western Australia, Perth, WA, Australia.; Aspetar Sports Medicine Hospital, Doha, Qatar., Sottas PE; BioKaizen Lab SA, Monthey, Switzerland., Bourdon PC; Sports Science Department, Aspire Academy, Doha, Qatar.; School of Health Sciences, University of South Australia, Adelaide, South Austalia, Australia., Nikolovski Z; Sports Science Department, Aspire Academy, Doha, Qatar., El-Gingo M; Sports Science Department, Aspire Academy, Doha, Qatar., Varamenti E; Sports Science Department, Aspire Academy, Doha, Qatar., Peeling P; Department of Sport Science, Exercise and Health, School of Human Sciences, University of Western Australia, Perth, WA, Australia.; Western Australian Institute of Sport, Mt Claremont, WA, Australia., Dawson B; Department of Sport Science, Exercise and Health, School of Human Sciences, University of Western Australia, Perth, WA, Australia., Schumacher YO; Aspetar Sports Medicine Hospital, Doha, Qatar.
Jazyk: angličtina
Zdroj: Drug testing and analysis [Drug Test Anal] 2018 Feb; Vol. 10 (2), pp. 294-300. Date of Electronic Publication: 2017 Jul 27.
DOI: 10.1002/dta.2219
Abstrakt: The haematological module of the Athlete's Biological Passport (ABP) has significantly impacted the prevalence of blood manipulations in elite sports. However, the ABP relies on a number of concentration-based markers of erythropoiesis, such as haemoglobin concentration ([Hb]), which are influenced by shifts in plasma volume (PV). Fluctuations in PV contribute to the majority of biological variance associated with volumetric ABP markers. Our laboratory recently identified a panel of common chemistry markers (from a simple blood test) capable of describing ca 67% of PV variance, presenting an applicable method to account for volume shifts within anti-doping practices. Here, this novel PV marker was included into the ABP adaptive model. Over a six-month period (one test per month), 33 healthy, active males provided blood samples and performed the CO-rebreathing method to record PV (control). In the final month participants performed a single maximal exercise effort to promote a PV shift (mean PV decrease -17%, 95% CI -9.75 to -18.13%). Applying the ABP adaptive model, individualized reference limits for [Hb] and the OFF-score were created, with and without the PV correction. With the PV correction, an average of 66% of [Hb] within-subject variance is explained, narrowing the predicted reference limits, and reducing the number of atypical ABP findings post-exercise. Despite an increase in sensitivity there was no observed loss of specificity with the addition of the PV correction. The novel PV marker presented here has the potential to improve the ABP's rate of correct doping detection by removing the confounding effects of PV variance.
(Copyright © 2017 John Wiley & Sons, Ltd.)
Databáze: MEDLINE
Externí odkaz: